Brand Name

Xdemvy

Generic Name
Lotilaner
View Brand Information
FDA approval date: August 14, 2023
Classification: Ectoparasiticide
Form: Solution

What is Xdemvy (Lotilaner)?

XDEMVY is indicated for the treatment of Demodex blepharitis. XDEMVY is an ectoparasiticide indicated for the treatment of Demodex blepharitis.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Functional Characterization of the Cat and Dog Wild-Type and Mutant MDR1 Carrier Proteins and Frequency of the MDR1 Gene Mutation in 800 Cats From Germany.
Functional Characterization of the Cat and Dog Wild-Type and Mutant MDR1 Carrier Proteins and Frequency of the MDR1 Gene Mutation in 800 Cats From Germany.
Journal: Journal of veterinary pharmacology and therapeutics
Published: October 21, 2025
Impact of lotilaner ophthalmic solution 0.25% on disease severity in patients with Demodex blepharitis and meibomian gland disease.
Impact of lotilaner ophthalmic solution 0.25% on disease severity in patients with Demodex blepharitis and meibomian gland disease.
Journal: Frontiers in medicine
Published: October 07, 2025
Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.
Efficacy of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel for the prevention of heartworm disease (Dirofilaria immitis) in dogs.
Journal: Parasites & vectors
Published: September 29, 2025
View All Latest Advances